Interleukin 22 protects colorectal cancer cells from chemotherapy by activating the STAT3 pathway and inducing autocrine expression of interleukin 8

Clinical Immunology

Volumn 154, Issue 2, 2014, Pages 116-126

  Wu, Tingyu ^a   Wang, Zhongchuan ^a   Liu, Yun ^a   Mei, Zubing ^a   Wang, Guanghui ^a   Liang, Zhonglin ^a   Cui, Ang ^a   Hu, Xuguang ^a   Cui, Long ^a   Yang, Yili ^a   Liu, Chen Ying ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Chemoresistance; Interleukin 22; Interleukin 8; STAT3

Indexed keywords

FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 22; INTERLEUKIN 6; INTERLEUKIN 8; OXALIPLATIN; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; PLATINUM COMPLEX; STAT3 PROTEIN, HUMAN;

ADULT; ARTICLE; AUTOCRINE EFFECT; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CELL INFILTRATION; CELL PROTECTION; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; CHEMORESISTANCE; COLORECTAL TUMOR; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; TREATMENT FAILURE; TUMOR CELL LINE;

CHEMORESISTANCE; INTERLEUKIN 22; INTERLEUKIN 8; STAT3;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOCRINE COMMUNICATION; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-8; INTERLEUKINS; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; STAT3 TRANSCRIPTION FACTOR; TREATMENT FAILURE;

EID: 84908470068     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.07.005     Document Type: Article

References (36)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63:11-30.
2. Dy G.K., Hobday T.J., Nelson G., et al. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. Clin. Colorectal Cancer 2009, 8:88-93.
3. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.
4. Castells M., Thibault B., Delord J.-P., Couderc B. Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int. J. Mol. Sci. 2012, 13:9545.
5. Frolova O., Samudio I., Benito J.M., et al. Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol. Ther. 2012, 13:858-870.
6. Dijkgraaf E.M., Heusinkveld M., Tummers B., et al. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res. 2013, 73:2480-2492.
7. Wang Y., Niu X.L., Qu Y., et al. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett. 2010, 295:110-123.
8. Wang Y., Qu Y., Niu X.L., et al. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine 2011, 56:365-375.
9. Ning Y., Manegold P.C., Hong Y.K., et al. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int. J. Cancer 2011, 128:2038-2049.
10. Zheng Y., Danilenko D.M., Valdez P., et al. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2006, 445:648-651.
11. Wolk K., Kunz S., Witte E., et al. IL-22 increases the innate immunity of tissues. Immunity 2004, 21:241-254.
12. Sonnenberg G.F., Fouser L.A., Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol. 2011, 12:383-390.
13. Huber S., Gagliani N., Zenewicz L.A., et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012, 491:259-263.
14. Jiang R., Tan Z., Deng L., et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011, 54:900-909.
15. Wu T., Cui L., Liang Z., et al. Elevated serum IL-22 levels correlate with chemoresistant condition of colorectal cancer. Clin. Immunol. 2013, 147:38. (Orlando, Fla).
16. Yao L., Zhang Y., Chen K., Hu X., Xu L.X. Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox. PLoS ONE 2011, 6:e24684.
17. Cheng W., Huang C., Chang M., et al. High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Brit. J. Cancer 2009, 100:1144-1153.
18. Tang W., Zhu Y., Gao J., et al. MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4. Brit. J. Cancer 2014, 110:450-458.
19. Hussein M., Hassan H. Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations. J. Clin. Pathol. 2006, 59:972-977.
20. Liu Y., Li P.-K., Li C., Lin J. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J. Biol. Chem. 2010, 285:27429-27439.
21. Taub R. Hepatoprotection via the IL-6/Stat3 pathway. J. Clin. Invest. 2003, 112:978-980.
22. Grivennikov S., Karin E., Terzic J., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
23. Hodge D.R., Hurt E.M., Farrar W.L. The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer 2005, 41:2502-2512.
24. Yeh M., Gharavi N.M., Choi J., et al. Oxidized phospholipids increase interleukin 8 (IL-8) synthesis by activation of the c-src/signal transducers and activators of transcription (STAT) 3 pathway. J. Biol. Chem. 2004, 279:30175-30181.
25. Bromberg J., Wang T.C. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009, 15:79-80.
26. Xiao H., Gulen M.F., Qin J., et al. The toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity 2007, 26:461-475.
27. Dumoutier L., Louahed J., Renauld J.-C. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J. Immunol. 2000, 164:1814-1819.
28. Galon J., Costes A., Sanchez-Cabo F., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
29. Salama P., Phillips M., Grieu F., et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 2009, 27:186-192.
30. Liu H., Zhang T., Ye J., et al. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol. Immunother. 2012, 61:1849-1856.
31. Putoczki T.L., Thiem S., Loving A., et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 2013, 24:257-271.
32. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin. Cancer Res. 2008, 14:6735-6741.
33. Fu J., Tang W., Du P., et al. Identifying microRNA-mRNA regulatory network in colorectal cancer by a combination of expression profile and bioinformatics analysis. BMC Syst. Biol. 2012, 6:68.
34. Wilson C., Wilson T., Johnston P.G., Longley D.B., Waugh D.J. Interleukin-8 signaling attenuates TRAIL-and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol. Cancer Ther. 2008, 7:2649-2661.
35. Benoy I.H., Salgado R., Van Dam P., et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin. Cancer Res. 2004, 10:7157-7162.
36. Zigler M., Villares G.J., Lev D.C., Melnikova V.O., Bar-Eli M. Tumor immunotherapy in melanoma. Am. J. Clin. Dermatol. 2008, 9:307-311.